Genomic Health Inc. is pleased to announce that the Florida Medicaid Program has implemented a coverage policy for the Oncotype DX Breast Cancer Assay. The effective date of coverage was retroactivated back to January 1, - Progesterone receptor - Document - PDFSEARCH.IO

First Page	Meta Content
	Genomic Health Inc. is pleased to announce that the Florida Medicaid Program has implemented a coverage policy for the Oncotype DX Breast Cancer Assay. The effective date of coverage was retroactivated back to January 1, Add to Reading List Document Date: 2014-12-17 10:57:38 Open Document File Size: 351,02 KB Share Result on Facebook City Geneva / Redwood City / / Company Genomic Health Inc. / / Country Switzerland / / / Facility European headquarters / / IndustryTerm treatment for early stage cancer / / MedicalCondition Tumor / early stage cancer / early stage breast cancer / cancer / Breast Cancer / DX Breast Cancer / / MedicalTreatment adjuvant chemotherapy / / Person Shawn J. Wheeler / / ProvinceOrState California / / Technology diagnostic tests / chemotherapy / / URL www.OncotypeDX.com / / SocialTag Oncology Oncotype DX Ribbon symbolism Cancer treatments Breast cancer HER2/neu Adjuvant therapy Estrogen receptor Progesterone Medicine

Genomic Health Inc. is pleased to announce that the Florida Medicaid Program has implemented a coverage policy for the Oncotype DX Breast Cancer Assay. The effective date of coverage was retroactivated back to January 1,Add to Reading List